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Treatment plans for prostate cancer patients undergoing stereotactic body radia-
tion therapy (SBRT) are often challenging due to the proximity of organs at risk. 
Today, there are no objective criteria to determine whether an optimal treatment 
plan has been achieved, and physicians rely on their personal experience to evaluate 
the plan’s quality. In this study, we propose a method for determining rectal and 
bladder dose constraints achievable for a given patient’s anatomy. We expect that 
this method will improve the overall plan quality and consistency, and facilitate 
comparison of clinical outcomes across different institutions. The 3D proximity of 
the organs at risk to the target is quantified by means of the expansion-intersection 
volume (EIV), which is defined as the intersection volume between the target and 
the organ at risk expanded by 5 mm. We determine a relationship between EIV and 
relevant dosimetric parameters, such as the volume of bladder and rectum receiving 
75% of the prescription dose (V75%). This relationship can be used to establish 
institution-specific criteria to guide the treatment planning and evaluation process. 
A database of 25 prostate patients treated with CyberKnife SBRT is used to validate 
this approach. There is a linear correlation between EIV and V75% of bladder and 
rectum, confirming that the dose delivered to rectum and bladder increases with 
increasing extension and proximity of these organs to the target. This information 
can be used during the planning stage to facilitate the plan optimization process, 
and to standardize plan quality and consistency. We have developed a method for 
determining customized dose constraints for prostate patients treated with robotic 
SBRT. Although the results are technology-specific and based on the experience of 
a single institution, we expect that the application of this method by other institu-
tions will result in improved standardization of clinical practice. 
PACS numbers: 87.55.-x, 87.55.D-, 87.55.de, 87.55.dk
Key words: prostate, stereotactic body radiation therapy, plan optimization,  
dose constraints
 
I. IntroduCtIon
The optimization and evaluation of a radiation therapy treatment plan is a complex process 
involving multiple steps. As a first step, the physician delineates target and organs at risk 
on the planning CT scan, often with the aid of other imaging sources (PET, MRI). Then the 
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physicist or dosimetrist runs the computer-based optimization engine until a solution is found 
that meets the dosimetric parameters requested by the physician. The solution of the planning 
problem is particularly challenging when optimizing plans for prostate cancer patients treated 
with CyberKnife stereotactic body radiation therapy (SBRT). Multiple conflicting goals exist in 
this case, such as target coverage, conformity and homogeneity of the dose distribution, spar-
ing of the organs at risks (bladder, rectum and urethra), and treatment time. Schlaefer et al.(1) 
describe a powerful multicriteria optimization approach for robotic radiosurgery. This method 
maps clinical goals into optimization steps and enables an optimal trade-off among different 
objectives by producing Pareto-efficient solutions.  
As a next step physicist, dosimetrist, and physician visually examine the dose distribu-
tion on the axial, sagittal, and coronal plane of the CT scan, and evaluate the target coverage 
and dose received by organs at risk using dose-volume histogram (DVH) analysis. A plan is 
deemed clinically acceptable if tumor coverage and dose tolerance to critical structures are 
within standard limits and/or meet physician expectations. The use of standard dose criteria in 
evaluating plan quality has however some limitations.(2) In particular, standard dose criteria 
do not account for the mutual disposition of target and organs at risk, which determines the 
difficulty of each individual treatment. In addition, modern radiotherapy equipment might 
provide superior dose distribution with lower dose to organs at risk, compared to conventional 
treatment modalities.
The main drawback of using equal dose criteria for every patient is that suboptimal treatment 
plans might still meet those criteria and, therefore, be deemed acceptable. Although physicist 
and physician experiences play a critical role in pushing the plan quality to the optimal limit, the 
process is somewhat subjective and lacks quantitative guidelines. Consequently, plans deemed 
acceptable might be far from the unknown optimality. 
The goal of this study is to help establish an objective method to evaluate the plan’s quality, 
which accounts for the individual patient’s geometry and is independent of physician and plan-
ner experiences. Prior to starting the optimization process, the method provides dose objectives 
for the individual case. These objectives are derived from a database of patients with similar 
characteristics and, therefore, can be considered achievable. 
Differences in target and critical structures definition among physicians introduce a source 
of uncertainty in establishing a user independent quality control method based on geometric 
criteria. Previous studies reported significant differences in treatment planning and DVH analysis 
due to uncertainty in target(3) and critical structures contouring.(4) 
In this work, we focus on prostate patients planned and treated with CyberKnife SBRT. However, 
a similar methodology can be developed for other treatment sites or treatment modalities.
The a priori knowledge of achievable dose constraints facilitates the treatment planning 
process and results in better plan quality. In addition, comparing dosimetric parameters of a 
newly developed treatment plan with institution-specific statistics provides a tool to control the 
plan quality and to improve the consistency among similar plans. We expect that this method 
will also facilitate interinstitution comparison of plan quality and eventually lead to standard-
ization of clinical practice. 
 
II. MAtErIALS And MEtHodS
The proposed method was developed for prostate patients treated with SBRT on the CyberKnife 
system (Accuray Inc., Sunnyvale, CA). In SBRT treatments, a high biologic-equivalent dose 
(BED) is delivered in few fractions (typically 2–5) with highly conformal distribution around 
the prostate and steep dose gradient at its periphery. Small treatment margins are possible, as 
the position of the prostate is monitored during the course of treatment every 30–60 seconds. 
Xie et al.(5) analyzed the intra-fraction prostate motion in 21 patients (105 fractions) treated 
with the CyberKnife system. They concluded that with an imaging interval of 30 seconds, target 
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margins could be kept as low as 1 mm and that 2 mm margin would be required if the imaging 
interval was increased to 60 seconds. Gottschalk et al.(6) reported similar results. 
Several SBRT treatment protocols are reported in the literature for the treatment of the prostate 
as both mono-therapy and post-pelvic irradiation boost.(7-10) The dose regimens and constraints 
for the organs at risk have been mainly derived from the experience in HDR brachytherapy, 
a well-established modality for delivering fewer high-dose fractions as monotherapy(11) or in 
combination with whole pelvis radiation therapy.(12) Table 1 reports a comparison of dose scheme 
and constraints published in the literature for HDR(13) and robotic SBRT protocols.(7-10) 
In order to establish quality control criteria for treatment plan evaluation at our institution, 
we reviewed the dosimetric parameters obtained on a database of 25 prostate patients. For 
consistency in plan quality, we considered only plans generated with the Iris variable aperture 
collimator (Accuray Inc.), which enables to deliver multiple-size radiation fields at each robot 
position.(14) Iris treatments do not require physical collimator exchange and are delivered in a 
single path traversal. Previous studies have shown that plans generated with three collimator 
apertures deliver better treatment quality (improved dose conformity, homogeneity and/or cov-
erage, and lower number of monitor units) compared to a single circular collimator.(14,15) The 
Iris collimator, therefore, offers the benefits of multiple-field-size treatments without increasing 
planning and delivery time. 
The use of existing clinical plans of comparable treatment characteristics enabled us to 
determine dosimetric criteria that are achievable for a given patient anatomy. 
The geometric distribution of organs at risk relative to the target plays a critical role in 
determining the achievable dose constraints. For example, standard dose criteria can be easily 
achieved for a patient with a small prostate and a large separation between target and organs at 
risk (Fig. 1, left). On the other hand, it is very difficult to achieve the same dose constraints in 
a patient with a large prostate and significant interface between target and organs at risk (Fig. 1, 
right). Treatment preparation, such as rectum and bladder filling, and the use of rectal balloons 
(for prostate immobilization and rectal wall sparing), bladder catheters (for constant bladder 
filling), and Foley catheters (for urethral delineation) influence the patient geometry and organ 
disposition. At our institution, patients are simulated with empty rectum and bladder (due to the 
prolonged treatment time, it is not feasible for the patients to maintain full bladder). In addition, 
the use of endorectal coils during MRI acquisition, and Foley catheters during simulation or 
treatment is not allowed to prevent deformation in the prostate gland.
In order to quantify the geometric relationship in the 3D space between the target volume 
and the organs at risk we used the concept of expansion-intersection histogram proposed by 
Table 1. Literature-based treatment parameters for HDR and robotic SBRT protocols.
 Parameter HDR(13) San Diego(8) UCSF(9) Erasmus(7) UCLA(10)
 Total dose 19 Gy 38 Gy 19 or 38 Gy 38 Gy 36.25 Gy
 Fractions 2 4 2 or 4 4 5
 Prescription  >50% >60% >67% 88%-92%
 PTV margin none 2-5 mm/0 post. 2 mm/0 post. 3 mm/0 post. 5 mm/3 mm post.
 PTV V100%a ≥90% V100%a ≥95% V100%a ≥95% V100%a ≥95% V100%a ≥95%
 Rectum V75%a <1 cc Wall V100%a = 0     V75%a <2 cc Wall V100%a = 0 V50%a <50%
      V80%a <20%
   Mucosab V75%a  = 0  Mucosab V75%a = 0 V90%a <10%
     V85%a <1 cc  V100%a <5%
 Bladder V75%a <1 cc V120%a = 0 V75%a <3 cc V110%a = 0 V50%a <40%
     V100%a <1 cc V100%a <10%
 Urethra V125%a <1 cc V120%a = 0 V120%a <10% V120%a = 0 
a Vxx: Volume of structure (PTV or organ at risk) receiving xx% of prescription dose.
b Mucosa: solid structure formed by a 3 mm contraction of the rectal wall.
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Tomatis et al.(16) We define the intersection volume between the target and the organ at risk 
expanded by 5 mm as EIV, expansion-intersection volume. A large EIV indicates that a large 
area of organ at risk faces the target, leading to a more difficult plan optimization. 
A.  treatment planning technique
For each patient, three gold fiducial markers are implanted into the prostate gland at least one 
week prior to CT simulation. The gold markers provide a reference frame to localize the posi-
tion of the prostate in the X-ray images acquired during treatment. A CT scan using 1.5 mm 
slice thickness is acquired, together with T1- and T2-weighted MRI imaging sequences. The 
CT and T2-weighted MRI scans are coregistered using a point-based registration to match the 
fiducial location. While the T2 sequence provides optimal visibility of prostate and urethra, the 
T1 sequence helps identify the fiducial markers, which produce a low signal in the T2-weighed 
images. The planning target volume (PTV) is created by a uniform 2 mm expansion of the 
prostate (contoured on the T2 sequence), except posteriorly to protect the rectum. The physi-
cian also contours organs at risk such as bladder, rectum, urethra, penis, testicles, bowel, and 
femoral heads. All organs at risk, except the urethra, are contoured on the planning CT. The 
bladder is contoured from its base to the dome. The rectum is contoured from the anus to the 
recto-sigmoid flexure. 
The “sequential optimization” (or “stepwise optimization”) method is used for plan genera-
tion.(1) This method provides a flexible approach to solve the planning problem and optimize 
multiple conflicting goals reproducing the decision-making process of a clinician.  Unlike 
inverse planning algorithms, which use relative weights and a single mathematical function 
to optimize all planning goals at once, sequential optimization addresses each goal separately 
in a predefined order. After each step, the feasibility of the solution is retained or relaxed by 
a user-defined value to improve plan quality at the next step. However, in the CyberKnife 
implementation of the sequential method, the relaxation parameter applies only to the last step 
in the sequential chain. This prevents major improvements in plan quality after step 2. The 
sequential optimization method possesses the right characteristics for scripting. Scripts (or plan 
templates) greatly reduce the variability of different treatment planning skills and help improve 
the standardization among similar plans. 
For prostate patients, a planning template is used at our institution. Beams intersecting the 
testicles are disabled, and field sizes ranging from the largest aperture that fits the PTV con-
tour down to the 12.5 mm diameter opening are selected. Three asymmetric shells are created 
Fig. 1. Anatomy of prostate patients. Examples of favorable (left) and unfavorable (right) patient anatomy for a prostate 
SBRT treatment. Linear dimensions of bladder-PTV and rectum-PTV interface are displayed on the same scale.
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around the PTV with larger margins in the lateral direction and tighter margins in the anterior–
posterior direction, to improve rectum and bladder sparing. Shells are tuning structures used 
by the optimization algorithm to achieve a conformal dose distribution around the target and 
control the dose gradient at its periphery. The distance between shell and PTV is 1–4 mm for 
the first shell, 6–12 mm for the second shell, and 15–25 mm for the third shell. The use of thin 
shells and dose-volume constraints for planning robotic radiosurgery is reported in the paper 
by Schlaefer et al.(17) This article discusses a specific example for a prostate case. 
A maximum of 200 monitor units (MUs) per beam per fraction is set in order to limit the 
beam-on time from each direction, therefore preventing a “finger-like” dose distribution. The 
dose distribution has “fingers” when the isodose line corresponding to 50% of the prescription 
dose is not shaped around the target, but protrudes for several centimeters away from it. Properly 
placed shells also help reducing this effect. The maximum MU per node is set to be slightly 
larger than the maximum MU per beam to enable the use of multiple beams per node, while 
avoiding skin hotspots due to predominant beam entry points. In some cases, the definition of 
a planning-specific target that does not overlap with bladder and rectum, and does not include 
the urethra, facilitates the planning process. 
The sequential optimization script is run to achieve the following clinical goals: i) to cover 
95% of PTV with 100% of the prescription dose; ii) to keep the volume of urethra receiving 
120% of the prescription dose (V120%) less than 0.1 cc; iii) to minimize the volume of rectum 
receiving 75% of the prescription dose (V75%); iv) to minimize the volume of bladder receiving 
75% of the prescription dose (V75%); and v) to obtain a dose distribution highly conformal 
around the target, with no hot spots in normal tissue.
After a plan of acceptable quality is achieved, beam and time reduction tools are used to 
obtain the best compromise between treatment efficiency and dosimetric quality.(18) 
B.  training cohort
Eleven of the 25 patients in the training cohort were treated with SBRT monotherapy using a 
dose of 38 Gy in 4 fractions. Fourteen patients were treated with SBRT boost. Among these, 
seven patients received a dose of 19 Gy in 2 fractions and seven patients received a dose of 
21 Gy in 2 fractions, according to a dose escalation protocol. To assess the robustness of the 
method to contouring uncertainties, patients contoured by three physicians were included in 
our study. Two physicists were involved in the treatment planning process.
The average PTV volume is 58.3 cm3 (range 11.3–148.3 cm3), the average bladder volume 
is 130.8 cm3 (range 47.8–385.5 cm3), and the average rectum volume is 102.0 cm3 (range 
45.4–365.8 cm3). For all plans, target coverage ≥ 95%, and prescription isodose-line > 60% 
are achieved. The average number of beams is 209 (range 112–360), and the average treatment 
time (excluding setup time) is 43 minutes (range 27–60 minutes).
For each plan, the following parameters are recorded and analyzed: i) EIV of rectum and 
bladder; ii) V75% of rectum and bladder; iii) V120% of urethra; iv) conformity index (nCI). 
The conformity index describes how well the prescription isodose volume (PIV) conforms 
to the target volume (TV) and it is defined as: nCI = TV × PIV / (TIV)2, where TIV is the target 
volume inside the prescription isodose volume. The average nCI was 1.24 (range 1.14–1.41), 
and the average urethra V120 was 0.03 cc (range 0–0.19 cc).  
In this analysis, we use V75% of bladder and rectum and V120% of urethra as the key 
dosimetric parameters to evaluate plan quality. This choice reflects our clinical practice and is 
based on the experience with HDR brachytherapy.(12)
The V75% values of bladder and rectum are plotted as a function of the EIV values of bladder 
and rectum. A linear regression analysis is performed in order to model the relationship between 
these two parameters. Prediction intervals, representing the intervals where 90% and 95% of 
future observations will fall, are also calculated. The prediction intervals enable to compare a 
new plan to our institutional standards and provide a method for quality control.
167  descovich et al.: dose constraints for prostate SBrt 167
Journal of Applied Clinical Medical Physics, Vol. 14, no. 5, 2013
C.  Validation cohort
The robustness of the method is tested on five new prostate cases. For all cases, the EIVs of 
bladder and rectum are calculated a priori and used to determine the expected values of V75%. 
These values serve as guidelines during the plan optimization process. 
 
III. rESuLtS 
A.  training cohort
A linear correlation between V75% and EIV is found for EIV values up to 10 cm3, followed 
by a saturation of V75% for larger EIV values.
Figure 2 reports the V75% of bladder plus rectum (total V75%) plotted as a function of the 
EIV of bladder plus rectum (total EIV). For all but two plans (marked with an open circle) 
our institution’s dose constraints are achieved. In addition, for patients with small EIV, a total 
V75% considerably lower than the limit is obtained. From this plot, it emerges that all data 
points should fall below two lines: a first threshold line representing the institution-specific 
dose constraints (i.e., total V75% < 5 cm3), and a second, empirical threshold line representing 
a feasible improvement in dosimetric parameters due to favorable patient anatomy (i.e., small 
EIV). One plan (marked with an open square in Fig. 2) fulfills the total V75% dose constraints 
(line 1), but is over the previously defined empirical threshold line (line 2).
The threshold lines were used to predict achievable V75% values of bladder plus rectum 
for the three outliers, and the treatments were replanned. In all three cases, dose objectives 
below the threshold could be achieved for bladder and rectum, while maintaining 95% PTV 
coverage, good dose conformity (nCI 1.17–1.24) and sparing of urethra (V120% < 0.1cc). An 
experienced radiation oncologist reviewed the new plans and compared them with the original 
versions. In all three cases, an improvement in plan quality was noted. 
Fig. 2. Correlation between V75% and EIV of bladder and rectum. V75% of bladder plus rectum (total V75%) plotted 
as a function of EIV of bladder plus rectum (total EIV). The open circles represent data points that are above the dose 
constraints: total V75% <5 cm3. The open square represents the data point that is above the empirical threshold line.
168  descovich et al.: dose constraints for prostate SBrt 168
Journal of Applied Clinical Medical Physics, Vol. 14, no. 5, 2013
Figure 3 is an update of Fig. 2, where the data for the three outliers are replaced with 
the replanned data (marked as open circles). A regression analysis for the data points with 
EIV < 10 cm3 provides a reasonable linear correlation (R2 = 0.76) between the total V75% 
and EIV. The 90% and 95% prediction intervals are also displayed. For data points with 
EIV > 10 cm3, the horizontal threshold line representing the institution-specific dose constraints 
(total V75% < 5 cm3) provides the method for quality control, and the prediction intervals are 
not calculated.
Fig. 3. Correlation between V75% and EIV of bladder and rectum — re-optimized plans. V75% of bladder plus rectum 
(total V75%) plotted as a function of EIV of bladder plus rectum (total EIV). Correlation line and prediction intervals are 
displayed. The open circles represent data for the re-optimized treatment plans.
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B.  Validation cohort
For all new prostate cases, it was possible to obtain clinically acceptable plans with (total EIV, 
total V75%) coordinates falling within the prediction intervals. Figure 4 displays the location of 
the new data points (open squares) in the (total EIV, total V75%) graph. The a priori knowledge 
of achievable V75% values facilitates the treatment planning process. Plans were generated by 
a physicist specialized in robotic radiosurgery planning in less than one day.
 
IV. dISCuSSIon
We presented an objective method, based on clinical experience, to evaluate the quality and 
consistency of prostate SBRT plans. This method enables to determine whether a satisfactory 
plan has been obtained without relying on personal experience. In our definition, a satisfac-
tory plan meets the clinical goals in terms of target coverage, organs at risk sparing, and dose 
conformity, and therefore is consistent with the clinical objectives at our institution. 
The linear correlation between EIV and V75% of bladder and rectum confirms that the dose 
delivered to bladder and rectum increases with increasing extension of the organs area fac-
ing the target. For a given EIV value, the linear fit enables to determine a priori optimal dose 
objectives for the organs at risk. This knowledge facilitates the treatment planning process in 
terms of both planning efficiency and plan quality, and provides a means to detect abnormal 
plan behavior.
In our analysis, the dose objectives for bladder and rectum are combined in a single param-
eter, the total V75%. The correlation between the total V75% and total EIV is indeed stronger 
than the correlation between V75% and EIV of bladder and rectum analyzed separately. This 
behavior can be explained by considering possible geometrical mutual dispositions of prostate 
and organs at risk, as displayed in Fig. 5. In the schematic drawings (Fig. 5(a) to 5(d)), prostate, 
bladder and rectum have the same size, but different mutual disposition. In Fig. 5(a), bladder 
and rectum are far from the prostate and therefore their EIVs are small; in (b) bladder EIV is 
large and rectum EIV is small; in (c) bladder EIV is small and rectum EIV is large; in (d) both 
organs are facing the prostate and therefore their EIVs are large. In Figs. 5(b) and (c), the treat-
ment plan can be optimized so that the 5% fraction of PTV volume receiving less than 100% of 
the prescribed dose (acceptable PTV coverage is 95%) is entirely concentrated at the interface 
with the bladder or with the rectum, respectively. In this way, the portion of bladder or rectum 
facing the prostate is mostly spared because the dose gradient starts already inside the prostate. 
Conversely, in Fig. 5(d) both organs at risk are facing the target, and a compromise for the loca-
tion of the dose gradient has to be reached. Figure 5 demonstrates that the dose delivered to the 
Fig. 4. Correlation between V75% and EIV of bladder and rectum — validation data. V75% of bladder plus rectum (total 
V75%) plotted as a function of EIV of bladder plus rectum (total EIV). The open squares represent the validation data.
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rectum depends not only on its proximity to the target, but also on the proximity of the bladder 
to the target. Similarly, the dose delivered to the bladder depends on the rectum location.
In the optimization algorithm, user-defined dose constraints are set in order to minimize the 
dose delivered to bladder and rectum. By properly adjusting constraints and optimization steps 
in the sequential workflow, it is possible to either balance the V75% of bladder and rectum 
to a similar value, or to prioritize the sparing of one organ versus the other, depending on the 
detailed clinical assessment. 
The total EIV analysis returns the value of V75% of bladder plus rectum for a given 
patient anatomy. The achievable V75% of rectum and bladder, separately, can be estimated as 
follows:
 Bladder V75% = f * Total V75% (1)
   
 Rectum V75% = (1-f) * Total V75% (2)
where f is a parameter with values ranging between 0 and 1. In general, f = 0.5 can be used. 
However, for large EIV it is generally preferred to keep rectum V75% < 2 cm3 and bladder 
V75% < 3 cm3. In this case, f = 0.6 is used.
A similar interplay is observed between the sparing of the organs at risk and the dose con-
formity around the target. Figure 6 shows the total V75% versus the total EIV separated in two 
groups: 1) plans with nCI < 1.25 (black triangles), and 2) plans with nCI ≥ 1.25 (open squares). 
A slightly stronger linear correlation between V75% and EIV emerges from the two groups 
(R2 = 0.83 and R2 = 0.77 for plans with low nCI and high nCI, respectively). Two almost par-
allel correlation lines are obtained from the two datasets, demonstrating that for a given EIV 
value, there are two alternative approaches to optimize the V75% values, one corresponding to 
a more conformal plan (nCI < 1.25) and one corresponding to a less conformal plan (nCI ≥ 1.25). 
Although some differences are observed between the linear fits for the different conformity 
levels, these results are not statistically significant. Prioritizing dose conformity, sparing of 
bladder and sparing of rectum is a clinical decision that needs to be evaluated on a case-by-case 
basis. For patients with favorable anatomy, physicians may also consider escalating the dose, 
Fig. 5. Geometrical disposition of prostate and organs at risk.
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while maintaining safe dose limits to the organs at risks. A method for estimating the limits of 
dose escalation for prostate radiotherapy has been described by Roach et al.(19)
We have established a method to determine achievable dose constraints for bladder and 
rectum prior to treatment planning. This method is based on an empirical relationship between 
EIV and V75% observed on a cohort of 25 patients. The choice of investigating the 75% dose 
level reflects our clinical practice and it is derived from the well-established experience in HDR 
brachytherapy. Choosing a different dose level might lead to a different relationship with EIV. 
A detailed characterization of the sensitivity to the selected dose level is outside the scope of 
this work.
The focus of this work is in the proposed methodology rather than the specific criteria and 
results obtained. The proposed criteria should not be considered as dose tolerance for critical 
organs, but as a guideline to improve institutional standards. Indeed, one limitation of this 
method is that it is institution- and technology-specific. However, being based on a measur-
able quantity (such as the EIV), this method could be easily validated by other institutions for 
intercomparison of plan quality. Differences in target and critical structures definition among 
physicians/institutions result in different dose-volume histogram (DVH) characteristics and 
make it difficult to compare clinical outcomes. Therefore, it is important to evaluate dosimetric 
parameters in relationship to a parameter accounting for the proximity of the organs at risk to 
the target. Interinstitution studies are required to further test the robustness of this method to 
contouring uncertainties.
We believe that this method could be particularly useful to institutions starting a new prostate 
SBRT program, or exploring advantages of new technologies.
 
V. ConCLuSIonS
A new method for objectively evaluating the quality of prostate SBRT plans is proposed. This 
method provides achievable dose constraints for bladder and rectum taking into account the 
patient’s anatomy. The knowledge of achievable dose constraints facilitates the treatment plan-
ning process, identifies suboptimal plans, and provides a means to control plan quality and 
consistency. This method is now routinely used in our clinical practice.
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Fig. 6. Correlation between V75% and EIV of bladder and rectum — conformity index. Total V75% as a function of total 
EIV for plans with low nCI (black triangles) and high nCI (open squares). The two correlation lines are also displayed.
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